08:00 , Apr 1, 2002 |  BioCentury  |  Product Development

Guidant spreading its stent bets

Guidant Corp.'s decision to license Novartis AG's everolimus anti-proliferative compound for use in drug-eluting stents shouldn't be seen as a vote of no confidence in its Achieve paclitaxol-eluting stents, according to the company. Instead, GDT...
08:00 , Mar 11, 2002 |  BC Week In Review  |  Clinical News

Actinomycin-D stent: Pilot

Data from the first 90 patients in GDT's pilot ACTION trial showed that the actinomycin-D stent was not effective in preventing restenosis. GDT said that patients treated with the stent had a high target lesion...
08:00 , Mar 11, 2002 |  BioCentury  |  Finance

Ebb & Flow

The good news is that biotech almost kept pace with NASDAQ last week; the bad news is it has a ways to go to catch up with the composite on a year-to-date basis. The NASDAQ...
08:00 , Mar 7, 2002 |  BC Extra  |  Clinical News

Guidant halts ACTION

GDT halted ACTION, a clinical trial of actinomycin-D eluting stent, after preliminary results showed that it was not effective in preventing restenosis....